- $32.07bn
- $32.84bn
- $4.22bn
- 94
- 19
- 93
- 77
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 26.18 | ||
PEG Ratio (f) | 2.25 | ||
EPS Growth (f) | 13.16% | ||
Dividend Yield (f) | 0.98% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 6.93 | ||
Price to Tang. Book | 24.81 | ||
Price to Free Cashflow | 29.94 | ||
Price to Sales | 7 | ||
EV to EBITDA | 23.23 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 20.43% | ||
Return on Equity | 22.39% | ||
Operating Margin | 26.92% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 2,606.57 | 2,957.01 | 3,196.82 | 3,578.13 | 4,222.99 | 4,666.36 | 4,997.8 | 12.53% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -2.03 | +33.63 | -24.54 | +61.38 | +14.6 | +25.33 | +11.13 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company’s segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers.
Directors
- Peter Farrell NEC (79)
- Robert Douglas PRE (61)
- Michael Farrell CEO (49)
- Brett Sandercock CFO (54)
- Bobby Ghoshal CEX (53)
- Jim Hollingshead CEX (58)
- Justin Leong CEX (44)
- Urvashi Tyagi CTO
- David Pendarvis CAD (62)
- Ronald Taylor LED (73)
- Carol Burt IND (63)
- Jan De Witte IND (57)
- Karen Drexler IND (61)
- Harjit Gill IND (56)
- Richard Sulpizio IND (71)
- Last Annual
- June 30th, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 31st, 1994
- Public Since
- June 1st, 1995
- No. of Shareholders
- 28
- No. of Employees
- 10,140
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 146,886,657
- Address
- 9001 Spectrum Center Blvd, SAN DIEGO, 92123-1438
- Web
- https://www.resmed.com/
- Phone
- +1 8587462400
- Auditors
- KPMG LLP
Latest News for RMD
Upcoming Events for RMD
Dividend For R1MD34.SA - 0.6201 BRL
Dividend For RMD.AX - 0.0480 USD
Dividend For RMD.N - 0.4800 USD
Q4 2024 Resmed Inc Earnings Release
Q1 2025 Resmed Inc Earnings Release
Similar to RMD
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
As of Today at 19:18 UTC, shares in Resmed are trading at $218.06. This share price information is delayed by 15 minutes.
Shares in Resmed last closed at $218.06 and the price had moved by -3.21% over the past 365 days. In terms of relative price strength the Resmed share price has underperformed the S&P500 Index by -20.87% over the past year.
The overall consensus recommendation for Resmed is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Resmed dividend yield is 0.86% based on the trailing twelve month period.
Last year, Resmed paid a total dividend of $1.88, and it currently has a trailing dividend yield of 0.86%.Looking ahead, shares in Resmed are due to go ex-dividend on 2024-05-08 and the next dividend pay date is 2024-06-13.
Resmed are due to go ex-dividend on 2024-05-08 and the next dividend pay date is 2024-06-13. The historic dividend yield on Resmed shares is currently 0.86%.
To buy shares in Resmed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $218.06, shares in Resmed had a market capitalisation of $32.07bn.
Here are the trading details for Resmed:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: RMD
Based on an overall assessment of its quality, value and momentum Resmed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Resmed is $209.89. That is 3.75% below the last closing price of $218.06.
Analysts covering Resmed currently have a consensus Earnings Per Share (EPS) forecast of $7.63 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Resmed. Over the past six months, its share price has outperformed the S&P500 Index by +32.31%.
As of the last closing price of $218.06, shares in Resmed were trading +26.52% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Resmed PE ratio based on its reported earnings over the past 12 months is 26.18. The shares last closed at $218.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Resmed's management team is headed by:
- Peter Farrell - NEC
- Robert Douglas - PRE
- Michael Farrell - CEO
- Brett Sandercock - CFO
- Bobby Ghoshal - CEX
- Jim Hollingshead - CEX
- Justin Leong - CEX
- Urvashi Tyagi - CTO
- David Pendarvis - CAD
- Ronald Taylor - LED
- Carol Burt - IND
- Jan De Witte - IND
- Karen Drexler - IND
- Harjit Gill - IND
- Richard Sulpizio - IND